December 28, 2009 - The Medical College of Wisconsin will license a novel molecular imaging technology designed to rapidly diagnosis cell death in organs such as the brain and heart. The technology, using imaging probes with a radiopharmaceutical compound, was invented by Ming Zhao, Ph.D., assistant professor of biophysics. The probes bind to dead and dying cells making them useful for detecting acute cell injury and cell death. When the active component of this molecule is attached to a radioactive tracer, it can be used in nuclear medicine imaging techniques, such as positron emission tomography (PET) or single photon emission computed tomography (SPECT), to produce three-dimensional images of where this cell death is occurring. "Imaging agent discovery and development is an important aspect in molecular and medical imaging research," Zhao said. "The process is critical for the improvement of existing imaging technologies and for early detection of acute cell death, cancerous tissue growth and major vessel diseases." He said the ability to image dead and dying cells can have major clinical benefits. For example, it could allow oncologists to rapidly monitor tumor response to a specific therapy. Another potential application is for rapid diagnosis of myocardial infarction. Often patients come into ER complaining of chest pain and need to have an expensive overnight hospital stay so they can be monitored while their lab results are being processed. This compound could allow clinicians to noninvasively image the heart and determine within a few hours if the patient actually had a heart attack or something else. The university announced today it signed a licensing agreement with GE Healthcare to further evaluate and develop the technology with the option to commercialize it. For more information: www.mcw.edu
If you enjoy this content, please share it with a colleague
Related Content
April 10, 2024 — Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next ...
April 5, 2024 — RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, today announced ...
March 29, 2024 — Magnetic resonance imaging (MRI) is a cornerstone in the landscape of medical diagnostics, celebrated ...
February 21, 2024 — Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next ...
February 15, 2024 — According to a release issued by the U.S. Food and Drug Administration (FDA), Philips is recalling ...
February 14, 2024 — PanTera, the Belgian joint venture created by IBA and SCK CEN to secure large-scale production of ...
February 12, 2024 — IBA, a world leader in particle accelerator technology and a world-leading provider of dosimetry and ...
February 9, 2024 — A novel PET imaging technique can noninvasively detect active inflammation in the body before ...
February 6, 2024 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) held its 2024 SNMMI Mid-Winter Meeting ...
January 23, 2024 — Siemens Healthineers announces the Food and Drug Administration (FDA) clearance of syngo Virtual ...